UCB's Global Corporate Website
Welcome to UCB in the United States

Sep

30

UCB Announces a Head-to-Head Study Evaluating BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

Jun

12

UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

May

06

Evolving Expectations for Arthritis Management

Nov

09

Advancing Rheumatic Disease Treatment

Dec

07

The Lancet Publishes Results from Two Bimekizumab Phase 3 Studies in Psoriatic Arthritis

Nov

17

Shaping the Future of Psoriatic Arthritis Care in Rural Settings

Nov

10

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis

Nov

09

Moving the Conversation Forward in Rheumatology – UCB at ACR Convergence 2022

Nov

08

UCB Reinforces Commitment to Rheumatology With 15 Abstracts Including New Late-Breaking Data at ACR Convergence 2022

Sep

01

UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress